Samira El Bouazzaoui

Author

Erasmus MC

Also Known As

S. El Bouazzaoui, S. el Bouazzaoui, Samira El Bouazzaoui, Samira el Bouazzaoui, Soukayna Bouazzaoui

Publications

454

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Erasmus University Rotterdam Amphia Ziekenhuis

About

Samira El Bouazzaoui is an author at Erasmus MC specializing in urology, oncology, and molecular diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	117
2	Pathology	2	2	74
3	Cancer Research	2	2	60
4	Genetics	1	1	17
5	Statistical Genetics	1	1	17

Samira El Bouazzaoui

Publications

433

Citations

H-Index

Page 1

	Year	Citations
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Journal for ImmunoTherapy of Cancer	2020	70
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients Sander Bins, Edwin A. Basak, Samira El Bouazzaoui, British Journal of Cancer	2018	64
Sex Difference in Formation of Propofol Metabolites: A Replication Study Eva Choong, Irena Loryan, M. Lindqvist, Basic & Clinical Pharmacology & Toxicology	2013	58
Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers Chris H. Bangma, Stacy Loeb, Martijn B. Busstra, European Urology UrologyGenitourinary CancerMolecular MarkersCancer ScreeningMedicine	2013	57
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project) Monique J. Roobol, Chris H. Bangma, Samira El Bouazzaoui, Urologic Oncology Seminars and Original Investigations UrologyOncologyGenitourinary CancerBlu-p ProjectMedicine	2010	43
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy Mirjam de With, Daan P. Hurkmans, Esther Oomen‐de Hoop, Cancers	2021	40
Polymorphisms in <i>SLCO1B1</i> and <i>UGT1A1</i> are Associated with Sorafenib-Induced Toxicity Sander Bins, Anne Lenting, Samira El Bouazzaoui, Pharmacogenomics	2016	30
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients Sander Bins, Alwin D. R. Huitema, Pim Laven, Clinical Pharmacokinetics	2018	28
Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood Angela A.G. van Tilborg, Lucie C. Kompier, Irene Lurkin, PLoS ONE Recurrent Bladder CancerGenetic TestingUrologyGenitourinary CancerTumor Heterogeneity	2012	17
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD Mirjam de With, Leni van Doorn, Demi C. Maasland, Biomedicine & Pharmacotherapy	2023	16

Page 1